G.K.K. Lau

917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

G.K.K. Lau, Patrick Marcellin, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2009 · 40 citations

Medicine, Infectious Diseases, Pharmacology +8

103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP

Patrick Marcellin, Teerha Piratvisuth, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2008 · 39 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B

G.K.K. Lau, Teerha Piratvisuth, K.X. Luo et al. · Journal of Hepatology · 2006 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

Patrick Marcellin, Teerha Piratvisuth, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2009 · 27 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +4

Three‐day lansoprazole quadruple therapy for <i>Helicobacter pylori</i>‐positive duodenal ulcers: a randomized controlled study

Benjamin C.Y. Wong, W. H. Wang, W. M. Wong et al. · Alimentary Pharmacology & Therapeutics · 2001 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +15